Introducing New Insights at the SABCS 2024
Four groundbreaking studies surrounding the Breast Cancer Index (BCI) test are set to be unveiled at the upcoming San Antonio Breast Cancer Symposium (SABCS) 2024. A highlight includes preliminary findings that examine how the BCI test can pinpoint postmenopausal women diagnosed with hormone-receptor positive (HR+), early-stage, node-negative breast cancer who face minimal risks of distant recurrence. The full set of study results will be shared in Poster Session 1, as the scientific community gathers to focus on advancements in breast cancer diagnostics.
The Importance of Personalizing Treatment
Dr. Gerrit-Jan Liefers, a surgeon at Leiden University Medical Centre and the primary investigator of the study, emphasizes the significance of identifying patients who may not need extensive endocrine therapy due to their minimal risk of recurrence. "Given the tolerability issues many patients face with adjuvant endocrine therapy, understanding those candidates who may be at minimal risk of distant recurrence could enable healthcare providers to tailor treatment plans accordingly," he stated. This personalized approach aims to improve the quality of life for women experiencing distressing side effects related to prolonged therapy.
Validation of the Breast Cancer Index Test
The BCI test has previously achieved recognition as an essential biomarker within clinical practice guidelines. It is recommended by the NCCN Clinical Practice Guidelines in Oncology and ASCO Clinical Practice Guideline for its predictive capability in assessing the efficacy of extended endocrine therapy for women with HR+, early-stage breast cancer.
Recent evaluations introduce a refined Breast Cancer Index prognostic model that can identify individuals with a 10-year distant recurrence risk of less than 5%. Validation conducted within the Netherlands Cancer Registry cohort revealed promising outcomes, indicating the adjusted BCI model is significantly prognostic. The study results showed that 20% and 16% of subjects classified as minimal risk according to the BCI test had a remarkable low 10-year distant recurrence risk of 2.3% and 4.5%, respectively.
Future Advancements for Treatment Protocols
Dr. Jennifer Schneiders, the President of Diagnostic Solutions at Hologic, expressed enthusiasm about the potential applications of the BCI test. "While further validation is necessary before this prognostic assessment becomes widely available, these findings reflect an increased applicability of the BCI test in clinical settings," she said. By identifying women with a significantly lower chance of cancer recurrence, healthcare providers can weigh the possibility of reducing endocrine therapy and its accompanying side effects.
Additional Collaborative Studies at SABCS 2024
In tandem with the main study, three more investigative research proposals will be presented, offering valuable insights into the BCI test:
- Examining the relationship between Breast Cancer Index Test classifications and MSK-IMPACT Genomic Profiles within HR+/HER2- breast cancer patients.
- Studying the implications of NCCN/ASCO Guidelines and enhancements in Epic Software for optimizing the use of the BCI test in community cancer care.
- Investigating the correlation between Body Mass Index and the predictive accuracy of the Breast Cancer Index for extended therapy benefits.
Understanding the Breast Cancer Index Test
The Breast Cancer Index test is a novel, gene expression-based diagnostic tool designed to assist physicians in making informed treatment decisions for those facing early-stage, HR+ breast cancer. It plays a critical role in guiding oncology care teams and patients through the complexities of treatment options, weighing the importance of recurrence prevention against the risk of adverse treatment effects. This tool is widely acknowledged for its contribution to cancer staging based on molecular profiling, and it stands as the only test recognized by leading oncology guidelines to predict outcomes of extended endocrine therapy.
About Hologic
Hologic, Inc. is a renowned leader in women's health, committed to innovating medical technologies that improve detection, diagnosis, and treatment of health conditions related to breast health. As a forward-thinking organization, Hologic is dedicated to raising clinical care standards globally and aims to generate solutions that positively impact women's health.
Frequently Asked Questions
1. What is the Breast Cancer Index Test?
The Breast Cancer Index Test is a diagnostic tool that assesses hormone-receptor positive, early-stage breast cancer patients to tailor treatment decisions effectively.
2. What were the key findings from the studies presented at SABCS 2024?
The studies indicated the ability of the BCI test to identify patients at minimal risk for distant recurrence, enhancing personalized treatment approaches.
3. Who is leading the study on the Breast Cancer Index Test?
Dr. Gerrit-Jan Liefers, a surgeon from Leiden University Medical Centre, is the primary investigator of the studies being presented.
4. How does the BCI Test impact treatment plans for patients?
The BCI Test helps doctors evaluate whether patients require extensive endocrine therapy, potentially reducing unnecessary side effects for eligible individuals.
5. Where can I find more information about Hologic and its products?
Additional details about Hologic and its endeavors in women's health can be found by visiting the official Hologic website or their social media platforms.
